[1]徐克菲,罗保平,周用.参芪扶正注射液联合化疗治疗非小细胞肺癌系统评价/Meta分析文献质量评价[J].西部中医药,2021,34(09):70-76.[doi:10.12174/j.issn.2096-9600.2021.09.20]
　XU Kefei,LUO Baoping,ZHOU Yong.Literature Quality Evaluation of Meta Analysis/Systematic Evaluation of Shenqi Fuzheng Injection Combined with Chemotherapy in Treating Non-small Cell Lung Cancer[J].Western Journal of Traditional Chinese Medicine,2021,34(09):70-76.[doi:10.12174/j.issn.2096-9600.2021.09.20]
点击复制

参芪扶正注射液联合化疗治疗非小细胞肺癌系统评价/Meta分析文献质量评价
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
34
期数:
2021年09期
页码:
70-76
栏目:
出版日期:
2021-09-15

文章信息/Info

Title:
Literature Quality Evaluation of Meta Analysis/Systematic Evaluation of Shenqi Fuzheng Injection Combined with Chemotherapy in Treating Non-small Cell Lung Cancer
作者:
徐克菲, 罗保平, 周用
湖北省中医院，湖北 武汉 430074
Author(s):
XU Kefei, LUO Baoping, ZHOU Yong
Hubei Provincial Hospital of TCM, Wuhan 430074, China
关键词:
非小细胞肺癌; 系统评价; Meta分析; 多元评价; 参芪扶正注射液
Keywords:
NSCLC; systematic evaluation; Meta analysis; multiple evaluation; injection
分类号:
R734.2
DOI:
10.12174/j.issn.2096-9600.2021.09.20
摘要:
目的评价参芪扶正注射液联合化疗治疗非小细胞肺癌（non-small cell lung cancer，NSCLC）系统评价/Meta分析的文献质量。 方法计算机检索自建库起至2019年5月21日中国知网、中国生物医学文献数据库、维普期刊网、万方数据、PubMed、Cochrane Library、EMbase收录的参芪扶正注射液联合化疗治疗NSCLC系统评价/Meta分析的文献，对符合纳入标准的文献进行数据提取，从发表年份、设计类型、AMSTAR方法学质量、PRISMA报告学质量、同质性程度、发表偏倚等6个维度综合评价文献质量，计算分值和秩数得分，合成结果绘制成雷达图进行可视化表述。 结果共纳入10篇文献，6个维度的秩数平均分依次是7.5、7.67、6.67、6.5、3.83、5.5、5.17、8.83、7.83、6.67分，秩数平均分为6.62分；质量较高的有1篇，质量偏低的有3篇，主要原因集中在纳入文献的研究类型、前期研究方案缺乏、文献检索工作全面性方面欠充分、尚未说明利益冲突和排除的研究文献清单等。 结论本研究提示参芪扶正注射液联合化疗治疗NSCLC系统评价/Meta分析的文献质量有待提升，未来的研究应加强方法学质量和报告学质量，以提供更高质量的循证医学证据。
Abstract:
ObjectiveTo assess the literature quality of systematic evaluation/Meta-analysis of Shenqi Fuzheng injection combined with chemotherapy in the treatment of NSCLC. MethodsBy searching the literature of systematic evaluation/Meta-analysis of Shenqi Fuzheng injection combined with chemotherapy in the treatment of NSCLC since the establishment of the database to May 21, 2019 included in CNKI, CBM, VIP jornal network, Wanfang data, PubMed, Cochrane Library, EMbase by the computer, the data was extracted from the literature that met the inclusion criteria, and the quality of the literature was comprehensively assessed from six dimensions: publication years, the design type, AMSTAR methodological quality, PRISMA reportage quality, degree of homogeneity, publication bias and others, to calculate the scores and rank score, the synthetic results were drawn into radar charts for visual representation. ResultsAll ten papers were included, rank average scores of six dimensions were 7.5, 7.67, 6.67, 6.5, 3.83, 5.5, 5.17, 8.83, 7.83 and 6.67 points, rank average score was 6.62 points; there was one article with high quality and three articles with lower quality, the main causes focused on the research types included in the literature, the lack of preliminary research scheme, the insufficient comprehensive literature retrieval, the list of research literature that has not explained the conflict of interest and excluded, etc. ConclusionThe study reveals that the literature quality of systematic evaluation/Meta-analysis of Shenqi Fuzheng injection combined with chemotherapy in the treatment of NSCLC needs to be lifted, the future research should enhance the quality of methodology and reportage in order to provide the evidence-based medicine of higher quality.

相似文献/References:

[1]宋春燕,王翠英.参芎葡萄糖联合放疗治疗局部晚期非小细胞肺癌50例临床观察[J].西部中医药,2013,26(01):89.
　SONG Chunyan,WANG Cuiying.Clinical Observation on ShenXiong Glucose Combined with Radiotherapy for 50 Cases of Local Non-small-cell Lung Cancer at Advanced Stage[J].Western Journal of Traditional Chinese Medicine,2013,26(09):89.
[2]任芳,徐厚谦△.黄芪注射液治疗糖尿病肾病有效性及安全性的系统评价[J].西部中医药,2014,27(01):77.
　REN Fang,XU Houqian.Systematic Review of the Effectiveness and Safety of HuangQi Injection in Treating Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2014,27(09):77.
[3]席彩霞,杨国泉,苏安平,等.贞芪益气胶囊联合 GP 方案治疗晚期非小细胞肺癌的临床研究[J].西部中医药,2014,27(09):4.
[4]王晓怀,寇嘉宁,潘文,等.黄芪注射液治疗脑梗死的Meta分析[J].西部中医药,2014,27(10):67.
[5]闫乾,陈锋△,黄有荣,等.活血化瘀中药制剂治疗脊髓型颈椎病有效性和安全性的系统评价*[J].西部中医药,2015,28(02):53.
[6]王舒雅,欧光顺,陈虹△,等.小儿智力糖浆对比利他林治疗儿童注意缺陷多动障碍疗效和安全性的系统评价[J].西部中医药,2015,28(02):67.
[7]魏春秀.老年股骨粗隆间骨折内固定术后康复护理疗效的系统评价[J].西部中医药,2015,28(04):69.
[8]赖乾,智方圆,袁振洁.单纯针刺与药物治疗周围性面瘫疗效的系统评价[J].西部中医药,2015,28(07):59.
[9]廖绛阳,张红△.血府逐瘀汤加味配合γ-刀治疗气虚血瘀证中晚期非小细胞肺癌30例[J].西部中医药,2015,28(10):98.
[10]魏海东,王晓平,万毅新,等.康艾注射液联合NP方案治疗非小细胞肺癌50例疗效观察[J].西部中医药,2012,25(09):57.
　WEI Hai-dong,WANG Xiao-ping,WAN Yi-xin,et al.Kang′ai Injection and NP Therapy in the Treatment for 50 Cases of Non-Small-Cell Lung Cancer[J].Western Journal of Traditional Chinese Medicine,2012,25(09):57.

备注/Memo

备注/Memo:
徐克菲（1984—），女，硕士学位，主治医师。研究方向：儿童肿瘤疾病的中西医结合防治。
更新日期/Last Update: 2021-09-15